News coverage about Cara Therapeutics (NASDAQ:CARA) has been trending somewhat positive on Saturday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cara Therapeutics earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 48.4356375230526 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Cara Therapeutics’ (CARA) “Buy” Rating Reaffirmed at Seaport Global Securities (americanbankingnews.com)
- Cara Therapeutics, Inc. (CARA) performed -10.79% – Monthly upward Move – The Stocks News (press release) (thestocksnews.com)
- Zacks Investment Research Upgrades Cara Therapeutics (CARA) to Hold (americanbankingnews.com)
- Cara Therapeutics, Inc. (CARA) stock closes Yesterday with $11.77 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Cramer’s lightning round: With so many great bank stocks, stay away from Wells Fargo (finance.yahoo.com)
CARA stock opened at $12.09 on Friday. Cara Therapeutics has a 52-week low of $11.11 and a 52-week high of $28.50. The firm has a market cap of $406.67, a P/E ratio of -6.33 and a beta of 2.92.
Several research firms have issued reports on CARA. HC Wainwright set a $22.00 price target on shares of Cara Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 19th. Janney Montgomery Scott upgraded shares of Cara Therapeutics from a “neutral” rating to a “buy” rating and decreased their price target for the stock from $27.00 to $21.00 in a research report on Monday, February 12th. BidaskClub lowered shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. Zacks Investment Research upgraded shares of Cara Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, ValuEngine upgraded shares of Cara Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, February 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $24.59.
In other Cara Therapeutics news, SVP Frederique Ph.D. Menzaghi sold 15,000 shares of Cara Therapeutics stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $15.00, for a total transaction of $225,000.00. Following the completion of the sale, the senior vice president now owns 122,000 shares of the company’s stock, valued at approximately $1,830,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Derek T. Chalmers sold 5,400 shares of Cara Therapeutics stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.00, for a total transaction of $81,000.00. Following the sale, the chief executive officer now directly owns 1,071,392 shares of the company’s stock, valued at approximately $16,070,880. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 35,900 shares of company stock worth $538,560. Corporate insiders own 7.70% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Cara Therapeutics (CARA) Share Price” was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3295280/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-cara-therapeutics-cara-share-price.html.
About Cara Therapeutics
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.